American pharmaceutical companies accused of carrying out clinical trials with Chinese military The revelation came in a letter penned by Republican and Democratic leaders on the House Select Committee on the Chinese Communist Party (CCP) to the commissioner of the Food and Drug Administration (FDA), Robert Califf.
One of the studies they focused on in their review of American clinical trials that included Chinese military hospital sites was for the Alzheimer's disease drug donanemab by Eli Lilly.
It will stop pharmaceutical companies from doing business with the firms in question, which could significantly compromise their bottom line.
In their letter, they explained: “These collaborative research activities raise serious concerns that critical Intellectual Property is at risk of being transferred to the [Chinese military] or being co-opted under the People’s Republic of China’s National Security Law.” They also expressed reservations about how much the results of clinical trials produced by China can be trusted.
In the letter, they pressed him to supply information about these clinical trials for new medications.
Legislation was introduced earlier this year that proposes putting a stop to federal contracts with specific Chinese biotech firms that are believed to present a national security risk to the U.S.
The letter states that hundreds of clinical trials for drugs have been carried out at medical centers and hospitals in China that are affiliated with the People's Liberation Army (PLA) at sites such as the PLA's Air Force Medical University and the PLA's General Hospital and Medical School.
No comments:
Post a Comment